Are Quality Metrics in Inflammatory Bowel Disease Rooted on Substantial Quality Evidence? A Systematic Review.

Background And Aims: Quality metrics were established to develop standards to help assess quality of care, yet variation in inflammatory bowel disease (IBD) clinical practice exists. We performed a systematic review to assess the overall quality of evidence cited in formulating IBD quality metrics.

Methods: A systematic search was performed on PubMed, MEDLINE, and EMBASE.

Isolated Intestinal Angioedema Secondary to a Food Allergen.

Intestinal angioedema is the dilatation or thickening, or both, of a segment of bowel. It is a diagnostic phenomenon that manifests itself clinically as acute abdominal pain, diarrhea, and emesis. Generally, this condition occurs in tandem with angioedema of the face and tongue and/or in association with the use of an angiotensin-converting enzyme inhibitor (ACE-I).

A novel player: cyclosporine therapy in the management of inflammatory bowel disease.

Amongst other indications, cyclosporine therapy has emerged as a novel agent for the management of severe refractory ulcerative colitis (UC). In the historic population of patients receiving cyclosporine therapy-namely solid organ transplant patients-renal toxicity has proven to be a significant mitigating side effect limiting the therapeutic window. However, dose-limiting sequelae amongst patients receiving cyclosporine for inflammatory bowel disease (IBD) have not been as significant.